Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
作者机构：Department of Interventional TherapyPeking University Cancer Hospital and InstituteKey Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Beijing 100142China
出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)
年 卷 期：2020年第12卷第6期
页 面：663-676页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by Beijing Municipal Science and Technology Commission(Z181100010118001) Foundation of Chinese Geriatric Oncology Society(CGOS-01-2012-1-00800) National Key R and D Program of China(2017YFC0114004) National Natural Science Foundation of China(81971717)
主 题：Hepatocellular carcinoma Transcatheter arterial chemoembolization Hepatic arterial infusion chemotherapy Oxaliplatin Fluorouracil Sorafenib
摘 要：BACKGROUND There is little evidence of combining sorafenib with hepatic arterial infusion chemotherapy(HAIC)after transarterial chemoembolization(TACE)for intermediate and advanced hepatocellular carcinoma(HCC).It is important to identify that patients with intermediate and advanced HCC are most likely to benefit from this combination *** To investigate the safety and clinical outcomes of sorafenib combined with HAIC with folinic acid,5-fluorouracil(5-FU),and oxaliplatin(FOLFOX)after TACE for intermediate and advanced *** This prospective phase II study enrolled patients with intermediate and advanced HCC who underwent treatment with sorafenib combined with *** patients initially received the standard 400 mg dose of sorafenib twice daily before *** at our institute with intermediate and advanced HCC underwent routine ***,the catheter used for embolization was kept in place in the hepatic artery,and oxaliplatin was intraarterially administered for 6 h,followed by 5-FU for 18 h,and folinic acid was intravenously administered for 2 *** primary endpoints were safety,as evaluated by the Common Terminology and Criteria for Adverse Events version 4.0,and 12-mo progression-free survival(PFS),as analyzed by the Kaplan-Meier *** secondary endpoints,the objective response rate(ORR)was evaluated by the modified Response Evaluation Criteria for Solid Tumors,and survival time[overall survival(OS)]was analyzed by the Kaplan-Meier *** Sixty-six participants at our institute with intermediate and advanced HCC were enrolled in this prospective study(mean age,53.3±11.7 years).Approximately 56.1%of participants had Barcelona Clinic Liver Cancer(BCLC)stage C disease,and 43.9%had BCLC stage B *** ORR was 42.4%.The disease control rate was 87.9%.The grade 3-4 toxicities consisted of thrombocytopenia(4.5%),neutropenia(3.0%),and elevated aspartate aminotransferase(12.2%).Hand-foot skin reaction was also observed(40
维普期刊数据库